Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Population health and health sector cost impacts of the UK Soft Drinks Industry Levy: a modelling study

View ORCID ProfileLinda J Cobiac, View ORCID ProfileCherry Law, View ORCID ProfileRichard Smith, View ORCID ProfileSteven Cummins, View ORCID ProfileHarry Rutter, View ORCID ProfileMike Rayner, View ORCID ProfileOliver Mytton, View ORCID ProfileAdam D M Briggs, View ORCID ProfileHenning Tarp Jensen, View ORCID ProfileMarcus Keogh-Brown, View ORCID ProfileJean Adams, View ORCID ProfileMartin White, View ORCID ProfilePeter Scarborough
doi: https://doi.org/10.1101/2023.10.05.23296619
Linda J Cobiac
1Principal Research Fellow Griffith University, Parklands Drive, Southport, QLD, 4222, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Linda J Cobiac
Cherry Law
2Lecturer in Applied Economics University of Reading, Reading, RG6 6EU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cherry Law
Richard Smith
3Professor of Health Economics and Deputy Pro Vice Chancellor University of Exeter, Exeter, EX1 2LU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Smith
Steven Cummins
4Professor of Population Health & NIHR Senior Investigator Population Health Innovation Lab, Department of Public Health, Environments & Society, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven Cummins
Harry Rutter
5Professor of Global Public Health University of Bath, BA2 7AY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harry Rutter
Mike Rayner
6Professor of Population Health Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mike Rayner
Oliver Mytton
7Honorary Public Health Consultant Great Ormond Street Hospital Institute of Child Health, UCL, 30 Guilford St, London WC1N 1EH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oliver Mytton
Adam D M Briggs
8Honorary Associate Professor Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam D M Briggs
Henning Tarp Jensen
9Associate Professor in Macroeconomics and Simulation Modelling London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Henning Tarp Jensen
Marcus Keogh-Brown
10Associate Professor in Economic Modelling London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcus Keogh-Brown
Jean Adams
11Associate Professor MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean Adams
Martin White
12Professor of Population Health Research MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin White
Peter Scarborough
13Professor of Population Health Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter Scarborough
  • For correspondence: peter.scarborough{at}ndph.ox.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To model future impacts of the UK Soft Drinks Industry Levy (SDIL) on population health and health sector costs, and to estimate net monetary benefit to the health system.

Design Proportional multi-state lifetable modelling study

Setting United Kingdom

Population All children and adults

Intervention The SDIL is a two-tier levy of £0.18 per litre on drinks with between 5g and 8g of total sugars per 100mL, and £0.24 per litre on drinks with 8g or more of total sugars per 100mL. We estimated a per person reduction in sugar from previous interrupted time series analysis, which found an 8.0 g/household/week (95% confidence interval: 2.4 to 13.6) reduction in sugar in purchased drinks at one year after implementation.

Main outcome measures We evaluated impact of the sugar reduction on: (a) prevalence of overweight and obesity, obesity-related diseases and dental health out to 2050; and (b) lifetime population health (measured in quality-adjusted life years [QALYs]), change in costs to the health sector and the resulting net monetary benefit.

Results The model predicts that the SDIL will reduce prevalence of overweight and obesity in the UK by 0.18 percentage points (95% uncertainty interval: 0.059 to 0.31) for males and 0.20 percentage points (0.064 to 0.34) for females, for as long as the sugar-reduction effects of the SDIL are sustained. In the first ten years of implementation, the reductions in sugar and overweight/obesity are predicted to prevent 270,000 (35,000 to 600,000) dental caries, 12,000 (3,700 to 20,000) cases of type 2diabetes, 3,800 (1,200 to 6,700) cases of cardiovascular diseases, and 350 (110 to 590) cases of obesity-related cancer. For the current UK population, it is estimated the SDIL will add 200,000 QALYs (63,500 to 342,000) over their lifetime and avert £174 million (£53.6 to £319) in their costs of health care (discounted at UK Treasury rates). At a UK Treasury value of £60,000 per QALY, it is estimated the SDIL will produce a net monetary benefit of £12.2 billion (£3.88 to £20.8) for the health system.

Conclusion This study of the UK SDIL tiered tax on sugar content provides further evidence that sugar- sweetened beverage taxes have the potential to achieve meaningful improvements in population health and reduce health sector spending.

What is already known on this topic

  • Numerous modelling studies have shown that sugar-sweetened beverage taxes are likely to be cost-effective and improve population health, whether the tax is applied on the volume of product or to the sugar content (absolute or tiered), but there have been few modelling studies that have been informed by evaluation of real-world taxes.

  • A volumetric sugar-sweetened beverage tax of 1 peso per litre, implemented in Mexico in 2014, reduced purchases of sugar-sweetened beverages by 7.6% in the first two years, and health economic modelling estimated that it would be cost-effective from a health sector perspective.

  • In the UK, the Soft Drinks Industry Levy (SDIL), announced in March 2016 and implemented in April 2018, was designed as a tiered levy to encourage soft drink manufacturers to reduce sugar content. Follow-up at one year indicates that it has reduced purchases of sugar from drinks by 8.0 g/household/week (95% confidence interval: 2.4 to 13.6).

What this study adds

  • Population health modelling suggests that changes in sugar consumption due to the SDIL will reduce prevalence of overweight/obesity and related diseases and improve dental health in the UK, including 12,000 (95% uncertainty interval: 3,700 to 20,000) fewer cases of type 2 diabetes, 3,800 (1,200 to 6,700) fewer cases of cardiovascular diseases, 350 (110 to 590) fewer cases of obesity-related cancer, and 270,000 (35,000 to 600,000) fewer dental caries, in the first ten years after implementation.

  • Health economic modelling indicates that over the lifetime of the current UK population the SDIL could add 200,000 quality-adjusted life years (63,500 to 342,000) and avert £174 million (£53.6 to £319) in health care costs, leading to a net monetary benefit of £12.2 billion (£3.88 to £20.8) for the health sector.

  • This study of the UK SDIL tiered tax on sugar content provides further evidence that sugar- sweetened beverage taxes have the potential to achieve meaningful improvements in population health and reduce health sector spending.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research is supported by a project grant from the NIHR Public Health Research Programme (NIHR PHR 16/130/01). PS is supported by the NIHR Biomedical Research Centre at Oxford (IS-BRC-1215-20008). PS is supported by a BHF Intermediate Basic Science Research Fellowship (FS/15/34/31656). OM is supported by a UKRI Future Leaders Fellowship (MR/T041226/1). MR is supported by the NIHR Project Grant and the Nuffield Department of Population Health, Unviersity of Oxford. MW and JMA are supported by an intramural programme grant within the MRC Epidemiology Unit (MC/UU/00006/7).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data used to support the PRIMEtime model and the analyses conducted in this paper are available in the public domain, some with licensed agreements from relevant data archives (the UK Data Archive https://www.data-archive.ac.uk/).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data used to support the PRIMEtime model and the analyses conducted in this paper are available in the public domain, some with licensed agreements from relevant data archives (the UK Data Archive https://www.data-archive.ac.uk/).

https://www.data-archive.ac.uk/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 07, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Population health and health sector cost impacts of the UK Soft Drinks Industry Levy: a modelling study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Population health and health sector cost impacts of the UK Soft Drinks Industry Levy: a modelling study
Linda J Cobiac, Cherry Law, Richard Smith, Steven Cummins, Harry Rutter, Mike Rayner, Oliver Mytton, Adam D M Briggs, Henning Tarp Jensen, Marcus Keogh-Brown, Jean Adams, Martin White, Peter Scarborough
medRxiv 2023.10.05.23296619; doi: https://doi.org/10.1101/2023.10.05.23296619
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Population health and health sector cost impacts of the UK Soft Drinks Industry Levy: a modelling study
Linda J Cobiac, Cherry Law, Richard Smith, Steven Cummins, Harry Rutter, Mike Rayner, Oliver Mytton, Adam D M Briggs, Henning Tarp Jensen, Marcus Keogh-Brown, Jean Adams, Martin White, Peter Scarborough
medRxiv 2023.10.05.23296619; doi: https://doi.org/10.1101/2023.10.05.23296619

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13337)
  • Forensic Medicine (19)
  • Gastroenterology (896)
  • Genetic and Genomic Medicine (5128)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3251)
  • Health Policy (1137)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1012)
  • Infectious Diseases (except HIV/AIDS) (14611)
  • Intensive Care and Critical Care Medicine (908)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (521)
  • Neurology (4898)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (879)
  • Occupational and Environmental Health (795)
  • Oncology (2515)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (537)
  • Pediatrics (1297)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4189)
  • Public and Global Health (7482)
  • Radiology and Imaging (1700)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (545)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)